PembrolizumabMeSH concept

https://www.has-sante.fr/jcms/p_3420797/fr/keytruda-pembrolizumab-cancer-du-sein
2024
false
false
false
France
evaluation of the transparency committee
breast neoplasms
pembrolizumab
breast cancer
pembrolizumab
Childhood Breast Carcinoma
Pembrolizumab
neoplasm, malignant
Male Breast Carcinoma
Keytruda
pembrolizumab

---
https://www.has-sante.fr/jcms/p_3325579/fr/keytruda-pembrolizumab-cancer-de-l-endometre
https://www.has-sante.fr/jcms/p_3325589/fr/decision-n-2022-0085/dc/sem-du-17-mars-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-keytruda
https://www.has-sante.fr/jcms/p_3329013/fr/decision-n-2022-0109/dc/sem-du-31-mars-2022-du-college-de-la-haute-autorite-de-sante-modifiant-la-decision-n-2022-0085/dc/sem-du-17-mars-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-keytruda
2022
false
false
false
France
French
evaluation of the transparency committee
pembrolizumab
cancer
neoplasm, malignant
Endometrium cancer
Keytruda
endometrium
pembrolizumab
Endomet
endometrial neoplasms
pembrolizumab

---
https://www.has-sante.fr/jcms/p_3327389/fr/keytruda-pembrolizumab-cancer-de-l-œsophage
https://www.has-sante.fr/jcms/p_3327401/fr/decision-n-2022-0182/dp/sem-du-30-mars-2022-de-la-presidente-de-la-haute-autorite-de-sante-prise-au-nom-du-college-portant-autorisation-d-acces-precoce-de-la-specialite-keytruda
2022
false
false
false
France
evaluation of the transparency committee
Esophagus cancer
Esophagus
pembrolizumab
esophagospasm
cancer of esophagus
Keytruda
neoplasm, malignant
pembrolizumab
Esophagus
pembrolizumab
esophageal neoplasms

---
https://www.has-sante.fr/jcms/p_3325988/fr/keytruda-pembrolizumab-cancer-du-sein
https://www.has-sante.fr/jcms/p_3325999/fr/decision-n-2022-0084/dc/sem-du-17-mars-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-keytruda
2022
false
false
false
France
evaluation of the transparency committee
breast cancer
breast neoplasms
Keytruda
pembrolizumab
pembrolizumab
pembrolizumab
Breast cancer
neoplasm, malignant

---
https://pgtmsite.files.wordpress.com/2024/01/ad-pembro_rapport-final1.pdf
2022
Canada
drug information
neoplasm, malignant
quebec
pembrolizumab
carcinoma, non-small-cell lung
Nonmetastatic
CYRIB wt Allele
L1 Stage Finding
Metastatic
Daur Chinese
lupus erythematosus cell
Lower Esophageal Sphincter
Lung Non-Small Cell Carcinoma
metastatic to
L1 Mouse
small cell lung carcinoma
patients
Patient
has patient
LE cells
Due
Long Interspersed Nucleotide Element-1
Pembrolizumab
Identifier
Intent To Treat
Device-In-Use Domain
Metastatic Malignant Neoplasm
Deoxyuridine
B7-H1 Antigen
pembrolizumab
pembrolizumab
intention to treat analysis
Analysis
hospitals, university
neutrophils
Cancer Therapeutic Procedure
Analyzed
Description
INRG Stage L1

---
https://pgtmsite.files.wordpress.com/2024/01/mic_ad-pembro_final-1.pdf
2021
Canada
drug information
Ambulatory Care Facility
pembrolizumab
Clinical Batch
Clinical Lot
pembrolizumab
Clinical Data
Pembrolizumab
Clinical Relevance
pembrolizumab
Intervention Model

---
https://www.has-sante.fr/jcms/p_3296560/fr/keytruda-pembrolizumab-cancer-du-sein-triple-negatif
2021
France
evaluation of the transparency committee
Keytruda
Breast cancer
pembrolizumab
triple negative breast neoplasms
pembrolizumab
breast cancer
neoplasm, malignant
pembrolizumab
triplets

---
https://pgtmsite.files.wordpress.com/2024/01/protocole-ad-pembrolizumab_final.pdf
2020
Canada
drug information
pembrolizumab
pembrolizumab
pembrolizumab
Pembrolizumab Regimen
AD Regimen

---
https://pgtmsite.files.wordpress.com/2024/01/pembrolizumab_strategie-posologique.pdf
2018
Canada
drug information
pembrolizumab
Pembrolizumab
pembrolizumab
pembrolizumab
Strategy

---